Eli Lilly, the maker of the drug Mounjaro, said Thursday it expects the medication could be approved by the U.S. Food and Drug Administration for weight loss as early as the end of the year.
Prior studies among people with obesity without Type 2 diabetes have shown a weight loss within the range of 15% to 21%, depending on the dose of the medication given. Doctors will typically start out with a low dose of the injection and increase the dose after four weeks based on your body's response.Sandy Huffaker for The Washington Post via Getty Images
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: